GoAI
Get started
INVO Fertility, Inc. logo

INVO Fertility, Inc.

IVF

NASDAQHealthcareMedical - Devices

Open in GoAI

Regular session

$1.065

+$0.005 · +0.47%

Aug 24, 10:09 AM ET

IVF company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

56

Fair Value

Momentum

17

Strong Down

Sentiment

44

Mixed

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was established on January 5, 2007, and its operations are based in Sarasota, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Steven Shum
Listed since
Nov 2, 2020
Employees
41

Market position

Day range

Current $1.065

52-week range

Current $1.065

Open
$1.08
Previous close
$1.06
Volume
86.08K
0.03× average
Average volume
3.01M
Average daily volume
Market cap
1.9M USD
Beta
2.32
Market reference 1
50-day average
$1.2474
-14.62% below average
200-day average
$4.4865
-76.26% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.76M USD
P/E (TTM)
-0.57×
P/B (TTM)
0.14×
P/S (TTM)
0.25×
EV / EBITDA
-0.5×
Earnings yield
-5297.90%
Free cash flow yield
-1603.22%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
33.34%
Operating margin
-78.72%
Net margin
-70.18%
Return on equity
-322.85%
Return on assets
-115.35%
Return on invested capital
-49.95%

Financial health

Debt / equity
0.24×
Current ratio
0.27×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends239%-330%-898%-1467%Gross margin, FY2021: 96.51%Gross margin, FY2022: -3.48%Gross margin, FY2023: 35.96%Gross margin, FY2024: 44.00%Gross margin, FY2025: 36.96%Operating margin, FY2021: -125.39%Operating margin, FY2022: -1292.45%Operating margin, FY2023: -224.04%Operating margin, FY2024: -124.40%Operating margin, FY2025: -85.36%Net margin, FY2021: -159.97%Net margin, FY2022: -1324.81%Net margin, FY2023: -266.00%Net margin, FY2024: -139.25%Net margin, FY2025: -340.92%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 96.51%. Gross margin FY2022 -3.48%. Gross margin FY2023 35.96%. Gross margin FY2024 44.00%. Gross margin FY2025 36.96%. Operating margin FY2021 -125.39%. Operating margin FY2022 -1292.45%. Operating margin FY2023 -224.04%. Operating margin FY2024 -124.40%. Operating margin FY2025 -85.36%. Net margin FY2021 -159.97%. Net margin FY2022 -1324.81%. Net margin FY2023 -266.00%. Net margin FY2024 -139.25%. Net margin FY2025 -340.92%.

Income trends

Revenue

6.84M USD+4.73%

Operating income

−5.84M USD+28.13%

Net income

−23.32M USD-156.41%
Income trends across reported periods9.86M USD−2.21M USD−14.27M USD−26.34M USDRevenue, FY2021: 4.16M USDRevenue, FY2022: 822.2K USDRevenue, FY2023: 3.02M USDRevenue, FY2024: 6.53M USDRevenue, FY2025: 6.84M USDOperating income, FY2021: −5.22M USDOperating income, FY2022: −10.63M USDOperating income, FY2023: −6.77M USDOperating income, FY2024: −8.13M USDOperating income, FY2025: −5.84M USDNet income, FY2021: −6.65M USDNet income, FY2022: −10.89M USDNet income, FY2023: −8.03M USDNet income, FY2024: −9.1M USDNet income, FY2025: −23.32M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.16M USD. Revenue FY2022 822.2K USD. Revenue FY2023 3.02M USD. Revenue FY2024 6.53M USD. Revenue FY2025 6.84M USD. Operating income FY2021 −5.22M USD. Operating income FY2022 −10.63M USD. Operating income FY2023 −6.77M USD. Operating income FY2024 −8.13M USD. Operating income FY2025 −5.84M USD. Net income FY2021 −6.65M USD. Net income FY2022 −10.89M USD. Net income FY2023 −8.03M USD. Net income FY2024 −9.1M USD. Net income FY2025 −23.32M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.84M USD6.53M USD3.02M USD822.2K USD4.16M USD
Cost of goods sold4.31M USD3.66M USD1.93M USD850.77K USD145.05K USD
Gross profit2.53M USD2.87M USD1.09M USD−28.57K USD4.02M USD
Research and development—489.66K USD165.95K USD544.04K USD216.43K USD
Selling, general, and administrative7.69M USD9.08M USD7.49M USD9.98M USD9.02M USD
Operating expenses8.37M USD11M USD7.65M USD10.6M USD9.23M USD
Interest income———308 USD3.66K USD
Interest expense1.3M USD1.06M USD925.91K USD59.45K USD1.27M USD
Depreciation and amortization677.36K USD919.6K USD200.89K USD77.3K USD166.08K USD
Operating income−5.84M USD−8.13M USD−6.77M USD−10.63M USD−5.22M USD
Net income−23.32M USD−9.1M USD−8.03M USD−10.89M USD−6.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-245.89%
11 comparable reports
Latest EPS result
0.35
Estimate -0.7 · Beat by 150.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.99-17.42-39.83-62.24Q2 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ2 '26MetQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 30, 2025: actual -10.85, estimate -4.2, surprise -158.29%, Miss. Q2 2025, reported May 20, 2025: actual -15.04, estimate -0.72, surprise -1988.54%, Miss. Q3 2025, reported Aug 14, 2025: actual -3.18, estimate -0.72, surprise -341.67%, Miss. Q4 2025, reported Nov 17, 2025: actual -30.8, estimate -57.6, surprise +46.53%, Beat. Q2 2026, reported May 6, 2026: actual -2.75, estimate -2.75, surprise 0.00%, Met estimate. Q2 2026, reported Jun 22, 2026: actual -3.38, estimate -2.75, surprise -22.91%, Miss. Q3 2026, reported Aug 14, 2026: actual 0.35, estimate -0.7, surprise +150.00%, Beat. Q4 2026, reported Nov 23, 2026: actual —, estimate -0.65, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.82M2.34M1.87M1.39MQ2 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ2 '26MetQ2 '26MetQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 30, 2025: actual 1.69M USD, estimate 1.5M USD, surprise +12.40%, Beat. Q2 2025, reported May 20, 2025: actual 1.64M USD, estimate 1.61M USD, surprise +1.97%, Beat. Q3 2025, reported Aug 14, 2025: actual 1.86M USD, estimate 1.68M USD, surprise +11.24%, Beat. Q4 2025, reported Nov 17, 2025: actual 1.76M USD, estimate 1.81M USD, surprise -3.19%, Miss. Q2 2026, reported May 6, 2026: actual 1.93M USD, estimate 1.93M USD, surprise 0.00%, Met estimate. Q2 2026, reported Jun 22, 2026: actual 1.93M USD, estimate 1.93M USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 14, 2026: actual 2.18M USD, estimate 2.4M USD, surprise -9.20%, Miss. Q4 2026, reported Nov 23, 2026: actual —, estimate 2.71M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$20.00

1777.93% upside
Past 12 months12-month forecast

Price history unavailable

High $20.00Average $20.00Low $20.00

Recent analyst actions

1 institution
Maxim GroupupgradeHoldBuy

IVF news

globenewswire.com

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of…

Read source
benzinga.com

INVO Fertility Stock Surges Following Q2 Earnings Beat

Shares of INVO Fertility Inc. (NASDAQ:IVF) are surging Monday afternoon after the healthcare fertility company reported second-quarter financial results that significantly outperformed Wall Street expectations on…

Read source
globenewswire.com

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis…

Read source
benzinga.com

Why INVO Fertility Stock Is Surging Friday Afternoon

INVO Fertility Inc (NASDAQ:IVF) shares are surging Friday afternoon following a pair of key operational and regulatory milestones disclosed in a new SEC Form 8-K filing. Here's what investors need to know.

Read source
globenewswire.com

INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet

Read source
globenewswire.com

INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q

SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 27, 2026

1:5

Stock split

Effective Nov 28, 2025

1:8

Stock split

Effective Jul 21, 2025

1:3

Stock split

Effective Mar 18, 2025

1:12

Stock split

Effective Jul 28, 2023

1:20

Stock split

Effective Nov 9, 2020

5:8

IVF peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research IVF

research.disclaimer